The global treatment-resistant depression treatment market size is expected to be valued at USD 1.69 Billion in 2023. With the increasing prevalence of depression and anxiety disorders in adults, coupled with the aging population, the overall demand for Treatment-Resistant Therapeutics Treatment is projected to grow at a CAGR of 9.0% between 2023 and 2033, totaling around USD 4.0 Billion by 2033.
The rising occurrence of Treatment-Resistant Depression has generated consciousness regarding its treatment. Various market players are developing advanced drugs that can be administered through nasal and intravenous routes rather than the traditional oral route of administration. The traditional antidepressants used for this disorder treatment require at least 4 to 6 weeks to produce an effect with a risk of incomplete or poor outcomes through the oral route of administration, whereas the intranasal has been found to produce better results within hours of administration.
For instance, in January 2022, as per the article published by Pharmacopsychiatry, the novel pipeline antidepressant MIJ821 of Novartis Pharmaceuticals demonstrated a more significant reduction in depressive episodes within 24 hours of administration via infusion weekly among patients.
In addition, the overall findings displayed that treatment with intranasal esketamine in amalgamation with a novel oral antidepressant was more efficient than a placebo plus an oral administration. The intranasal esketamine showcased a prompt drop in depressive symptoms and postponed its relapse time. Such increasing research & development for advanced drugs through other routes of administration is projected to surge the demand for drugs, thereby augmenting the overall market growth.
| Data Points | Key Statistics |
|---|---|
| Treatment-Resistant Depression Therapeutics Market Value 2023 | USD 1.69 Billion |
| Treatment-Resistant Depression Therapeutics Market Projected Value (2033) | USD 4.0 Billion |
| Treatment-Resistant Depression Therapeutics Market CAGR (2023 to 2033) | 9.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for treatment-resistant depression therapeutics is projected to increase at a CAGR of 9.0% during the forecast period between 2023 and 2033, reaching a total of USD 4.0 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.3%.
According to Future Market Insights, a market research and competitive intelligence provider, the Treatment-Resistant Depression Therapeutics market was valued at USD 1.55 Billion in 2022. As per the World Health Organization (WHO), the prevalence of mental health disorders as well as conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment. Moreover, several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in the depression treatment market.
Increasing Drug Development Projects to Fuel the Market Growth
The rise in the prevalence of Treatment-Resistant Depression and the presence of few treatment options has stimulated the market players to initiate full-fledged research and development activities. Various major market players are focusing on developing new and innovative therapies in the market, citing the clinical benefits and a significant unmet need in treating the disorder globally.
Additionally, it is the leading cause of worldwide disability as conventional therapies are ineffective in a large patient pool, and novel therapies are needed to cater to this growing demand. Also, various pharmaceutical, as well as life science companies, are actively investing in clinical trials of potential pipeline candidates to introduce novel products for treatment. Further, such active participation from the public and private players in developing potential candidates under investigational studies escalates the demand for resistant depression treatment around the globe.
Increasing Prevalence of TRD Globally to Accelerate the Market Growth
The increase in the prevalence of this mood disorder is one of the major factors that is projected to boost the growth of the TRD Treatment market. TRD occurs when an individual hasn't responded to doses of two different antidepressants taken for an adequate time, usually six weeks. The increase in the prevalence of this medical condition has increased the demand for resistant depression therapeutics.
In addition, according to Springer's research article published in August 2021, major depression disorders affect over 300 million people worldwide, and approximately one-third of patients with MDD have treatment-resistant depression. The prevalence is also associated with disproportionate healthcare costs that have significant direct and indirect cost implications, which places considerable strain on healthcare and social resources.
The variability in the type of healthcare setting as well as accessibility to quality healthcare across the countries to assess unmet needs and treatment failure increases the demand for effective therapeutic measures. Such a rising prevalence of this disorder and disproportionate healthcare costs, which varies across the globe, are anticipated to surge the demand for an effective treatment thereby, fostering the overall treatment growth over the analysis period.
Principal Consultant
Poor Management of Disorders to Restrain the Market Growth
Despite increasing investment from market players in the TRD project for developing an effective therapeutic measure, there is poor management of this mood disorder, resulting in significant variations in how patients are being managed in real-world practice.
Moreover, the lack of clarity in diagnosing patients is a significant challenge for its treatment. Patients drop out or discontinue treatment due to poor or no positive outcomes. In addition, a cultural and social stigma toward reporting non-responsiveness to treatment, lack of therapeutic options, and inadequate guidelines for managing patients are cumulatively responsible for restraining the market growth.
According to a December 2020 study published by NIH, for the management of TRD, 41.0% of physicians reported treatment discontinuation and loss to follow-up as the top challenge, while 15.0% indicated a lack of therapeutic options as their biggest challenge. Another 14.0% and 13.0% were related to a lack of standardized TRD definitions and specific guidelines, respectively. In addition, the lack of clarity in guidelines for the diagnosis and management of this mood disorder patients, coupled with limited therapeutic measures is expected to hinder the market growth over the analysis period.
Advanced Healthcare Infrastructure in the Region to Fuel the Market Growth
The treatment-resistant depression therapeutics market in North America is expected to accumulate the highest market share of 50% in 2023. North America is the most lucrative region along with the highest market share. Factors such as the advanced healthcare infrastructure and healthcare spending are anticipated to fuel the growth of the Treatment-Resistant Depression Market during the forecast period. Also, increasing the adoption rate and demand will propel the treatment-resistance depression treatment market in this region.
In addition, in recent years, there has been a growing rate of adoption, and increasing demand for treatment-resistant depression is also expected to drive the regional market. The region is expected to hold the highest CAGR of 8.8% during the forecast period.
Growing Awareness Regarding Mental Disorders in the Region to Fuel the Market Growth
The treatment-resistant depression therapeutics market in Asia Pacific is expected to accumulate the highest market share of 49% in 2023. Asia Pacific is the most lucrative region along with the highest market share.
Asia Pacific is opening up the previously held taboo of mental health. With growing awareness about mental disorders, depression, and mental health, the regional segment of Asia Pacific is expected to show a promising rate of growth and give rise to lucrative business opportunities for the development of the market in the coming years. The region is expected to hold the highest CAGR of 8.7% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
NMDA Segment to beat Competition in Untiring Market
On the basis of drug type, the global Treatment-Resistant Depression Therapeutics market is dominated by the NMDA Segment, which accounts for a share of 49%. The growth of the NMDA segment is attributed to the increasing research studies for developing NMDA drugs to improve treatment outcomes.
Moreover, the larger patient population suffering from this disorder and FDA approval of NMDA drugs developed by the key market are expected to fuel segmental growth in the coming years. The segment is expected to hold a CAGR of 8.8% over the analysis period.
Hospital Pharmacies Segment to Drive the Treatment-Resistant Depression Therapeutics Market
Based on the Distribution Channel, the hospital pharmacies segment is expected to witness a significant growth of 47% in 2022, and the trend is expected to continue during the forecast period.
In the treatment of this mood disorder, a prescription for drugs from a medical professional is needed, this is a crucial reason attributable to the segment's growth. In addition, the expansion of hospital pharmacies owing to increasing investment by the public sector in the healthcare infrastructure in emerging countries is predicted to augment the segmental growth during the forecast period. The segment is expected to hold a CAGR of 8.7% over the analysis period.
Prominent players in the treatment-resistant depression therapeutics market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 9% from 2023 to 2033 |
| Market Value in 2023 | USD 1.69 Billion |
| Market Value in 2033 | USD 4 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Type, Distribution Channel, Region |
| Regions Covered | North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Janssen Pharmaceuticals; AbbVie Inc.; AstraZeneca; H. Lundbeck A/S; Sandoz International GmbH; Par Pharmaceutical Companies Inc.; Otsuka Holdings Co., Ltd. |
| Customization & Pricing | Available upon Request |
As of 2022, the market for Treatment-Resistant Depression Treatment was valued at USD 1.55 Billion, as per FMI
By 2023-end, demand for treatment-resistant depression treatment closed at a value of USD 1.69 Billion
From 2018 to 2022, Treatment-Resistant Depression Treatment demand expanded at a CAGR of 3.3%
From 2023 to 2033, treatment-resistant depression treatment demand is expected to flourish at a CAGR of 9%
By 2033, the market value of treatment-resistant depression treatment is expected to reach USD 4 Billion
By drug type, the NMDA segment of the treatment-resistant depression treatment constitutes the bulk of the market share of 49% in 2022
By distribution channel, the hospital pharmacies segment dominates the market with a share of 47% in 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. NMDA 5.2. Antidepressants 5.3. Antipsychotics 5.4. Other Drug Types 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Hospital Pharmacies 6.2. Drug Stores & Retail Pharmacies 6.3. Online Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia & Pacific 7.5. East Asia 7.6. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Eli Lilly Company 16.2. GlaxoSmithKline 16.3. Pfizer Inc. 16.4. Janssen Pharmaceuticals 16.5. AbbVie Inc. 16.6. AstraZeneca 16.7. H. Lundbeck 16.8. Sandoz International GmbH 16.9. Par Pharmaceutical Companies Inc. 16.10. Otsuka Holdings Co. Ltd. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Treatment-Resistant Depression Treatment Market
